Barclays Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target hoisted by analysts at Barclays from $25.00 to $29.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 10.80% from the stock’s previous close.

HIMS has been the topic of a number of other research reports. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a report on Tuesday, February 24th. Needham & Company LLC upgraded shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Monday. Truist Financial reaffirmed a “hold” rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Finally, Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $30.75.

Hims & Hers Health Stock Up 11.5%

Shares of HIMS stock traded up $2.70 on Wednesday, reaching $26.17. 51,621,830 shares of the company’s stock traded hands, compared to its average volume of 33,284,391. The company has a market capitalization of $5.97 billion, a P/E ratio of 51.21, a price-to-earnings-growth ratio of 4.24 and a beta of 2.55. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The business’s 50 day moving average price is $24.31 and its two-hundred day moving average price is $37.75.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same period in the prior year, the business earned $0.11 EPS. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. On average, equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has approved a stock buyback program on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. This represents a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 80,463 shares of company stock worth $2,846,696 in the last ninety days. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently made changes to their positions in HIMS. Pathway Capital Management LP bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at approximately $6,766,000. Steadview Capital Management LLC boosted its position in Hims & Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after purchasing an additional 311,845 shares during the period. State of Michigan Retirement System boosted its position in Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after purchasing an additional 678,600 shares during the period. Carnegie Investment Counsel grew its holdings in Hims & Hers Health by 25.4% during the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock valued at $17,238,000 after purchasing an additional 61,560 shares during the last quarter. Finally, BIT Capital GmbH grew its holdings in Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after purchasing an additional 938,728 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Strategic partnership with Novo Nordisk clears legal risk and enables HIMS to sell FDA‑approved Ozempic/Wegovy on its platform — a direct revenue driver and margin improver. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Positive Sentiment: Wave of analyst upgrades and price‑target increases (Needham, Barclays, Deutsche Bank, Citigroup, etc.) reflecting reduced legal risk and modeled GLP‑1 contribution. These upgrades support buy‑side interest. Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang
• Positive Sentiment: Unusually large call‑option activity (≈322k calls) indicates speculative/bullish positioning that can amplify upside momentum. Hims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)
• Neutral Sentiment: Corporate hire: Kathryn Beiser named Chief Communications Officer to lead external/internal messaging as the company scales — supports investor communications but not an immediate revenue catalyst. Hims & Hers Names Kathryn Beiser as Chief Communications Officer
• Neutral Sentiment: Product/platform expansion: HIMS is broadening its digital care services (new specialties, lab testing, global rollout) — supports longer‑term revenue diversification but will take time to show measurable impact. Hims and Hers Expands Consumer-Focused Digital Health Platform
• Negative Sentiment: High short interest and squeeze dynamics create volatility risk — gains can be sharp but also susceptible to rapid reversals once speculative pressure eases. Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade)
• Negative Sentiment: Regulatory / litigation backdrop and ongoing investigations remain a watch item despite the Novo truce; Q4 showed an EPS beat but a slight revenue miss — execution and regulatory clarity仍 important. Hims & Hers Health Investigation Initiated

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.